ºñ´ÙÀÚÁÖ100¹Ð¸®±×·¥(¾ÆÀÚ½ÃƼµò)
¾÷ü¸í : ¼¼¿¤Áø(À¯)
È¿´ÉÈ¿°ú
´ÙÀ½°ú °°Àº ȯÀÚÀÇ Ä¡·á;
1. °ñ¼öÇü¼ºÀÌ»óÁõÈıº (Myelodyplastic syndrome, MDS)
ºÒÀÀ¼ººóÇ÷(RA), ȯ»óöÀû¸ð±¸°¡ ÀÖ´Â ºÒÀÀ¼ººóÇ÷(RARS)(È£Áß±¸ °¨¼ÒÁõÀ̳ª Ç÷¼ÒÆÇ °¨¼ÒÁõÀ» ¼ö¹ÝÇϰųª ¼öÇ÷ÀÌ ¿ä±¸µÉ ¶§), °ñ¼ö¾Æ±¸ °úÀ× ºÒÀÀ¼ººóÇ÷(RAEB)
2. ¼¼°èº¸°Ç±â±¸(World Health Organization, WHO) ºÐ·ù¿¡ µû¸¥ 20~30% ¾Æ¼¼Æ÷¸¦ °®´Â ´Ù°è¿ ÀÌÇü¼ºÁõÀÇ ±Þ¼º°ñ¼ö¼º ¹éÇ÷º´(AML)
3. ¸¸¼º°ñ¼ö´ÜÇÙ±¸¼º ¹éÇ÷º´(CMML)
4. ¼¼°èº¸°Ç±â±¸(World Health Organization, WHO) ºÐ·ù¿¡ µû¸¥ °ñ¼ö ¾Æ¼¼Æ÷°¡ 30%¸¦ ÃÊ°úÇÏ´Â Á¶Ç÷¸ð¼¼Æ÷À̽Ä(haematopoietic stem cell transplantation, HSCT) ¹× ÁýÁßÇ×¾ÏÈÇпä¹ý¿¡ ÀûÇÕÇÏÁö ¾ÊÀº 65¼¼ ÀÌ»óÀÇ ¼ºÀÎ Áß ¼¼Æ÷À¯ÀüÇÐÀûÀ¸·Î °íÀ§Çè(poor cytogenetics)ÀÇ »õ·Î Áø´Ü¹ÞÀº ±Þ¼º°ñ¼ö¼º¹éÇ÷º´(acute myeloid leukaemia, AML) ȯÀÚÀÇ Ä¡·á
½ÄÇ°ÀǾà¾ÈÁ¤Ã»¿¡¼ ¿ë·®¿ë¹ý ¹× »ç¿ë»ó ÁÖÀÇ»çÇ× ¾Ë¾Æº¸±â
https://ezdrug.mfds.go.kr/#!CCBAA03F010